9-NYSE (Bilingue) Recap = Resumen Semanal = FEB 05, 2025

The CONSUMER Financial Protection Bureau reported that credit card balances surpassed $1.2 trillion in 2024, prompting discussions about evolving payment preferences and financial behavior. Industry leaders explained how younger consumers have shifted toward debit-based models and buy-now-pay-later services like Afterpay, which charge retailers rather than consumers and disable accounts immediately upon late payment. This consumer-driven demand reflects a broader rejection of traditional credit structures. Meanwhile, public companies discussed strong stock performance driven by revenue growth exceeding inflation, disciplined capital expenditure, and enhanced shareholder returns through dividends and buyback programs, with free cash flow expansion enabling increased payouts.

Healthcare and technology innovation dominated several segments. Pharmaceutical and medical device firms highlighted breakthrough developments including new treatments for ocular conditions like dry eye and glaucoma, the first biomimetic contact lens material since 1999, and FDA-approved colorectal cancer screening technology using decentralized clinical trials. Cell therapy manufacturing emerged as a critical growth area, with companies deploying automated platforms across smart factories to eliminate supply constraints and reduce costs while bringing biopharmaceutical production back to the United States. Digital health platforms discussed accessible online therapy matched through AI algorithms, while cross-border fintech solutions addressed financial inclusion challenges in markets like Brazil, where companies focus on customer education amid high interest rates and delinquency concerns.